New shingles vaccine trial aims to protect millions over 40
NCT ID NCT06851832
First seen Apr 08, 2026 · Last updated May 25, 2026 · Updated 7 times
Summary
This study tests a new recombinant shingles vaccine in 960 healthy adults aged 40 and older. The goal is to check the vaccine's safety and how well it boosts the immune system against the shingles virus. Participants receive the vaccine and are monitored for side effects and immune response over several months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xiangcheng County Center for Disease Control and Prevention
Xuchang, Henan, China
Conditions
Explore the condition pages connected to this study.